Relevant bibliographies by topics / American Medical Association. Meeting 1876 : Philadelphia, Pa.)

Contents

  1. Journal articles

Academic literature on the topic 'American Medical Association. Meeting 1876 : Philadelphia, Pa.)'

Author: Grafiati
Published: 29 July 2024
Last updated: 30 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'American Medical Association. Meeting 1876 : Philadelphia, Pa.).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "American Medical Association. Meeting 1876 : Philadelphia, Pa.)"

1

Saito, Akira, Hideyuki Ohzawa, Yuki Kaneko, et al. "Abstract 6379: Dipeptidyl peptidase-4 inhibitor impairs the outcomes of patients with type 2 diabetes mellitus after curative resection for colorectal cancer." Cancer Research 82, no. 12_Supplement (2022): 6379. http://dx.doi.org/10.1158/1538-7445.am2022-6379.

Full text
Abstract:
Abstract Background: Type2 diabetes mellitus(T2DM) is a risk factor for cancer. Recent studies have shown that DPP-4 inhibitor(DPP-4i) can either promote or suppress cancer progression. However, the detailed mechanisms remain unknown. Here, in this study, we investigated the effect of DPP-4i on tumor microenvironment and its effect on the prognosis of cancer patients. Method: We retrospectively examined the outcome of colorectal cancer (CRC) patients with T2DM who received curative surgery in Jichi Medical University Hospital and asked the impact of DPP-4i intake on their outcome. In addition,
APA, Harvard, Vancouver, ISO, and other styles
2

Park, Sehhoon, Junghoon Shin, Chan-Young Ock, et al. "Abstract 7658: Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a prognostic biomarker for pembrolizumab plus chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma." Cancer Research 84, no. 6_Supplement (2024): 7658. http://dx.doi.org/10.1158/1538-7445.am2024-7658.

Full text
Abstract:
Abstract Background: Programmed cell death ligand 1 (PD-L1) expression alone has limited predictive value for pembrolizumab plus 5-fluorouracil and platinum (PFP) therapy in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). An artificial intelligence (AI)-powered spatial tumor-infiltrating lymphocyte (TIL) analyzer may provide independent prognostic information. Methods: This study included 63 patients with locally incurable HNSCC who received first-line PFP at Samsung Medical Center. Patients were classified into inflamed phenotype (IP) or non-inflamed phenotype (NIP) bas
APA, Harvard, Vancouver, ISO, and other styles
3

Shen, Lin, Yongqian Shu, Kuaile Zhao, et al. "Abstract CT077: Association of tumor mutational burden (TMB) and clinical outcomes with tislelizumab versus chemotherapy in esophageal cell carcinoma (ESCC) from RATIONALE-302." Cancer Research 83, no. 8_Supplement (2023): CT077. http://dx.doi.org/10.1158/1538-7445.am2023-ct077.

Full text
Abstract:
Abstract Background: Programmed cell death protein 1 (PD-1) inhibitors are approved as second-line (2L) therapy for patients (pts) with ESCC. TMB is a predictive biomarker of response to immune checkpoint blockade in multiple cancers, but its role in ESCC is unclear. Here, we retrospectively investigated the association between TMB and clinical outcomes in the phase 3 RATIONALE-302 study of anti-PD-1 antibody tislelizumab (TIS) vs investigator-chosen chemotherapy (ICC) as 2L treatment for advanced unresectable/metastatic ESCC (NCT03430843). Methods: Genomic profiling was assessed on tumor tiss
APA, Harvard, Vancouver, ISO, and other styles
4

Gaspar, Cátia F., Natalie Y. Ngoi, Tin Tang, et al. "Abstract 963: Clinical impact of MTAP status in advanced cholangiocarcinoma: Genomic profile and response to treatment." Cancer Research 83, no. 7_Supplement (2023): 963. http://dx.doi.org/10.1158/1538-7445.am2023-963.

Full text
Abstract:
Abstract Background: MTAP-loss is an emerging biomarker guiding druggable targets in cholangiocarcinoma and almost exclusively occurs in the setting of 9p21 loss, which has itself been associated with reduced IO responsiveness and poorer survival outcomes on a pan-cancer analysis. We sought to understand the clinical impact of MTAP status on treatment and survival outcomes, in a clinical cohort of molecularly characterized advanced cholangiocarcinoma patients. Methods: We analyzed advanced cholangiocarcinoma patients treated and evaluated at MD Anderson Cancer Center, tested for MTAP. Clinical
APA, Harvard, Vancouver, ISO, and other styles
5

Grasso, Luigi, J. Bradford Kline, and Nicholas C. Nicolaides. "Abstract 1876: NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of potent payload by counteracting MUC16/CA125 effects." Cancer Research 83, no. 7_Supplement (2023): 1876. http://dx.doi.org/10.1158/1538-7445.am2023-1876.

Full text
Abstract:
Abstract Subsets of tumor-produced proteins, referred to as Humoral Immuno-Oncology (HIO) factors, can bind to IgG1 antibodies and suppress their immune-effector activities. Antibody-drug conjugates (ADCs) targeting tumor cell surface antigens can internalize and kill target cells upon liberation of their cytotoxic payload. Binding of the antibody component of an ADC by a HIO factor may potentially hamper the efficacy of a bound ADC. To assess any suppression of ADC’s activity by HIO factors, we evaluated the efficacy of a HIO-refractory ADC, NAV-001, and a HIO-bound ADC, SS1, both targeting m
APA, Harvard, Vancouver, ISO, and other styles
6

Tahk, Siret, Kai Virumae, Korneelia Anton, et al. "Abstract 1876: Development of therapeutic antibodies targeting the GLUT-1 transporter to restrict cancer cell growth." Cancer Research 84, no. 6_Supplement (2024): 1876. http://dx.doi.org/10.1158/1538-7445.am2024-1876.

Full text
Abstract:
Abstract Background: Upregulated glucose metabolism is one of the strategies cancer cells use to fuel their abnormal cell growth and division. Targeting the cancer-specific glucose transporter GLUT-1 is a promising approach to restrict glucose uptake and challenge the metabolic needs of tumor cells. Antibodies, as opposed to small molecule inhibitors, are an attractive modality to therapeutically target complex muti-pass membrane transporters. Here we report the development of antibodies that very specifically block the function of only GLUT-1. Methods: Monoclonal antibodies against GLUT-1 wer
APA, Harvard, Vancouver, ISO, and other styles
7

Xu, Kailun, Xiaoyang Yin, Tiannan Guo, Shu Zheng, and Yingkuan Shao. "Abstract 7093: Prediction of overall survival in stage II and III colon cancer through machine learning of rapidly-acquired proteomics." Cancer Research 84, no. 6_Supplement (2024): 7093. http://dx.doi.org/10.1158/1538-7445.am2024-7093.

Full text
Abstract:
Abstract The use of adjuvant therapy in stage II-III colon cancer (CC) has been controversial for decades. No markers or models now is satisfactory enough to be adopted widely by the medical community. Here, we analyzed the proteomics of paraffin-embedded tissue (FFPE) biopsy samples from 230 CC patients (stages II-III) with up to 10 years of survival by using pressure cycling technology (PCT) and data-independent acquisition (DIA) mass spectrometry. Using machine learning, we established a novel and practical protein-based clinical classification system for CC prognosis which was further veri
APA, Harvard, Vancouver, ISO, and other styles
8

Jeon, Junhyeok, Eujin Hong, and Hyun Uk Kim. "Abstract 4923: A systematic framework for predicting adverse drug reaction signals using medical data." Cancer Research 84, no. 6_Supplement (2024): 4923. http://dx.doi.org/10.1158/1538-7445.am2024-4923.

Full text
Abstract:
Abstract Prescribing a combination of medications is a common strategy to enhance the effectiveness of disease treatment. While this approach aims to improve therapeutic outcomes, it may lead to unintended adverse drug reactions (ADRs) due to interactions between prescribed drugs and individual factors. Recognizing the importance of ADRs, various machine learning models have been developed. However, these models face limitations, particularly in predicting reactions induced by three or more drugs and in accounting for individual patient factors, such as age and medical history. To address thes
APA, Harvard, Vancouver, ISO, and other styles
9

Cheung, Christian S., Nathan W. Sweeney, Zena M. Tiu, Cynthia Chmielewski, and Jennifer M. Ahlstrom. "Abstract 6287: Comparison of multiple myeloma provider for Black Americans and Caucasian Americans." Cancer Research 82, no. 12_Supplement (2022): 6287. http://dx.doi.org/10.1158/1538-7445.am2022-6287.

Full text
Abstract:
Abstract Background: Although Black Americans have 2-3 times multiple myeloma (MM) incidence and mortality as compared to Whites, increasingly research is demonstrating that many may have genetic characteristics that have better survival outcomes. Yet delayed diagnoses and inappropriate first lines of therapy often wipe out whatever “advantages” they may have had, keeping mortality statistics higher than would be expected (PMID: 25469920). For underserved populations, a number of commonly accepted disparities exist in myeloma, and more broadly, cancer care. Patients who receive treatment by a
APA, Harvard, Vancouver, ISO, and other styles
10

Gurjao, Carino, Edmond Chan, Michael J. Lee, et al. "Abstract 994: Single analyte profiling of the mutational, immune and microbiome landscape in african american colon cancer patients." Cancer Research 84, no. 6_Supplement (2024): 994. http://dx.doi.org/10.1158/1538-7445.am2024-994.

Full text
Abstract:
Abstract Colorectal cancer (CRC) disproportionately affects African American (AA) patients who experience a higher incidence and mortality than any other demographic groups in the United States. Yet molecular profiling in this population is scarce. Here, we performed whole-exome sequencing (WES) of 342 immediately snap-frozen tissues comprising AA CRC and matched, distant normal colon and identified distinct genomic drivers, DNA signatures, and, surprisingly, mosaic pathogenic mutations that are not present in the patient-matched CRC. We inferred T cell infiltration and tissue-resident microbi
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography